Atyr Pharma Inc. Insider Trading

ATYR

⊜ Compare

Last 12 months

Insiders bought 50K and sold 6K on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan.

Net open-market

+44K

1 buy · 3 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

1 / 3

executives and directors

Last open-market buy

May 2026

May 27, 2026

Get an email when ATYR's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
May 27	Paul Schimmel Director	Bought	100,000	$0.50	50K	4.8%	Form 4
Feb 4	Sanjay Shukla President and CEO	SoldNo plan	3,745	$0.98	4K	2.4%	Form 4
Feb 4	Jill Marie Broadfoot Chief Financial Officer	SoldNo plan	1,558	$0.98	2K	4.0%	Form 4
Feb 4	Nancy Denyes General Counsel	SoldNo plan	1,118	$0.98	1K	3.3%	Form 4
Oct 8, 2025 – Oct 9, 2025	Paul Schimmel Director	Bought 2 parts	1,000,000	$0.91 average	913K	91%	Form 4
Mar 17, 2025	Jane A Gross Director	Bought	3,750	$4.00	15K	63%	Form 4
Feb 4, 2025	Jill Marie Broadfoot Chief Financial Officer	SoldNo plan	1,254	$3.78	5K	3.8%	Form 4
Feb 4, 2025	Nancy Denyes General Counsel	SoldNo plan	899	$3.78	3K	3.3%	Form 4

May 27
Paul Schimmel
Director · bought 100,000 at $0.50
50K
4.8% of stake
Feb 4No plan
Sanjay Shukla
President and CEO · sold 3,745 at $0.98
4K
2.4% of stake
Feb 4No plan
Jill Marie Broadfoot
Chief Financial Officer · sold 1,558 at $0.98
2K
4.0% of stake
Feb 4No plan
Nancy Denyes
General Counsel · sold 1,118 at $0.98
1K
3.3% of stake
Oct 8, 2025 – Oct 9, 2025
Paul Schimmel
Director · bought 1,000,000 at avg $0.91
913K
91% of stake
Mar 17, 2025
Jane A Gross
Director · bought 3,750 at $4.00
15K
63% of stake
Feb 4, 2025No plan
Jill Marie Broadfoot
Chief Financial Officer · sold 1,254 at $3.78
5K
3.8% of stake
Feb 4, 2025No plan
Nancy Denyes
General Counsel · sold 899 at $3.78
3K
3.3% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ATYR, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with ATYR

CompareIntrinsic value

WINTWindtree Therapeutics Inc.

$0.00+0.00%10

ZIVOZivo Bioscience Inc.

$8.00+10.34%0

VIVSVivoSim Labs, Inc.

$0.15+8.71%10

AIMAIM ImmunoTech Inc.

$0.16+0.63%15

INMBInmune Bio Inc.

$1.33+0.76%10

SNTISenti Biosciences Inc.

$0.18-0.79%0

PALIPalisade Bio Inc.

$1.25+1.63%20

CRDFCardiff Oncology Inc.

$0.87+1.03%36

Spot a number that looks wrong? Check it in ATYR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ATYR

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.